Drug class
Pharmacological chaperone; alpha-galactosidase A stabiliser for Fabry disease
Mechanism of action
Reversibly binds the active site of amenable mutant alpha-galactosidase A (alpha-Gal A), stabilising the enzyme and promoting trafficking to lysosomes, where it can catabolise globotriaosylceramide and related substrates. It is only suitable for GLA variants demonstrated to be amenable to migalastat.
General use cases
- Treatment of adults with a confirmed diagnosis of Fabry disease and an amenable GLA variant based on the validated in-vitro amenability assay; not indicated for non-amenable variants or paediatric patients
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
